Prognostic Value of Hematological Markers in Head and Neck Cancer Patients With a History of Hematological Malignancy
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives Head and neck cancer can occur as a second primary tumorin patients with a history of hematological malignancy, and the pathological features of thoseare more aggressive than de novo primary head and neck cancer. However, research related tothe prognostic value of hematological markers in the head and neck cancer patients with a his-tory of hematological malignancy is scarce, so we performed this study. Subjects and Method We reviewed a total of 89 head and neck cancer patients with hemato-logical malignancy diagnosed at a single tertiary hospital between 1997 and 2021, and enrolled29. The analyzed hematological parameters included pre- and post-treatment hemoglobin, he-matocrit, lactate dehydrogenase, absolute neturophil count (ANC), absolute platelet count, ab-solute leukocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio. Results Hematological malignancy was diagnosed almost 62.14±96.10 months before headand neck cancer. The most common hematological malignancy was acute myeloid leukemia. The overall survival (OS) rate was lower in patients with second primary tumor than in thosewith de novo primary head and neck cancer. The cox-proportional hazard ratio analysis showedthat the post-treatment absolute neutrophil count was significantly correlated with disease-freesurvival but not with OS. Conclusion The post-treatment hematological profile, particularly ANC, can be considereda useful prognostic marker in the head and neck cancer patients with a history of hematologi-cal malignancy.
Abstract
Background and Objectives Head and neck cancer can occur as a second primary tumorin patients with a history of hematological malignancy, and the pathological features of thoseare more aggressive than de novo primary head and neck cancer. However, research related tothe prognostic value of hematological markers in the head and neck cancer patients with a his-tory of hematological malignancy is scarce, so we performed this study. Subjects and Method We reviewed a total of 89 head and neck cancer patients with hemato-logical malignancy diagnosed at a single tertiary hospital between 1997 and 2021, and enrolled29. The analyzed hematological parameters included pre- and post-treatment hemoglobin, he-matocrit, lactate dehydrogenase, absolute neturophil count (ANC), absolute platelet count, ab-solute leukocyte count, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio. Results Hematological malignancy was diagnosed almost 62.14±96.10 months before headand neck cancer. The most common hematological malignancy was acute myeloid leukemia. The overall survival (OS) rate was lower in patients with second primary tumor than in thosewith de novo primary head and neck cancer. The cox-proportional hazard ratio analysis showedthat the post-treatment absolute neutrophil count was significantly correlated with disease-freesurvival but not with OS. Conclusion The post-treatment hematological profile, particularly ANC, can be considereda useful prognostic marker in the head and neck cancer patients with a history of hematologi-cal malignancy.
참고문헌 (30)
- Mowery A, "Risk of head and neck cancer in patients with prior hematologic malignant tumors", JAMA Otolaryngol Head Neck Surg, 145(12), pp.1121~1127 (2019)
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- Won-Ju Park, "Twenty-year incidence trend of hematologic malignancies in the Republic of Korea: 1999‒2018", Blood Research, 56(4), pp.301~314 (2021), 대한혈액학회[DOI]
- Hisada M, "Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia : A population-based study", J Natl Cancer Inst, 99(3), pp.215~222 (2007)
- Kumar V, "Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia", Blood Cancer J, 9(10), pp.75~ (2019)
- Feller A, "The relative risk of second primary cancers in Switzerland : A population-based retrospective cohort study", BMC Cancer, 20(1), pp.51~ (2020)
- Fitzthum AD, "Chronic lymphocytic leukemia and second primary nonlymphoid malignancies : Cytopathologic study of 17 cases", J Am Soc Cytopathol, 10(3), pp.321~327 (2021)
- Ganzel C, "Prognostic factors in adult acute leukemia", Hematol Oncol Clin North Am, 25(6), pp.1163~1187 (2011)
- Gorczyca W, "Prognostic and predictive markers in hematologic neoplasms. A review", Pol J Pathol, 62(4), pp.189~205 (2011)
- Wang F, "Current and potential inflammation targeted therapies in head and neck cancer", Curr Opin Pharmacol, 9(4), pp.389~395 (2009)
- Arend R, "Neutrophilia and mortality in women with uterine carcinosarcoma", Int J Gynecol Cancer, 29(8), pp.1258~1263 (2019)
- Damar M, "Pretreatment neutrophil-lymphocyte ratio in salivary gland tumors is associated with malignancy", Otolaryngol Head Neck Surg, 155(6), pp.988~996 (2016)
- Koyama Y, "Absolute lymphocyte count, platelet-to-lymphocyte ratio, and overall survival in eribulin-treated HER2-negative metastatic breast cancer patients", Cancer Diagn Progn, 1(5), pp.435~441 (2021)
- Hajian-Tilaki K, "Receiver operating characteristic(ROC)curve analysis for medical diagnostic test evaluation", Caspian J Intern Med, 4(2), pp.627~635 (2013)
- Hanley JA, "The meaning and use of the area under a receiver operating characteristic(ROC)curve", Radiology, 143(1), pp.29~36 (1982)
- Lai CY, "Exact confidence interval estimation for the Youden index and its corresponding optimal cutpoint", Comput Stat Data Anal, 56(5), pp.1103~1114 (2012)
- Dong C, "Second primary neoplasms among 53 159haematolymphoproliferative malignancy patients in Sweden, 1958-1996: A search for common mechanisms", Br J Cancer, 85(7), pp.997~1005 (2001)
- Laconi E, "Cancer as a disease of old age : Changing mutational and microenvironmental landscapes", Br J Cancer, 122(7), pp.943~952 (2020)
- Chen MH, "Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer", J Cancer Res Clin Oncol, 135(12), pp.1783~1790 (2009)
- Watanabe A, "Absolute neutrophil count predicts postoperative prognosis in mass-forming intrahepatic cholangiocarcinoma", Anticancer Res, 39(2), pp.941~947 (2019)
- Frejborg E, "Role of cyclooxygenase-2 in head and neck tumorigenesis", Int J Mol Sci, 21(23), pp.9246~ (2020)
- Chen YF, "High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma", Eur Arch Otorhinolaryngol, 270(3), pp.1009~1017 (2013)
- Cooke KR, "The biology of chronic graft-versus-host disease : A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graftversus-host disease", Biol Blood Marrow Transplant, 23(2), pp.211~234 (2017)
- Grkovic L, "Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity", Leukemia, 26(4), pp.633~643 (2012)
- Douglas CM, "Long-term survival of head and neck squamous cell carcinoma after bone marrow transplant", Head Neck, 42(11), pp.3389~3395 (2020)
- Wang H, "Prognostic values of LDH and CRP in cervical cancer", Onco Targets Ther, 13, pp.1255~1263 (2020)
- Harris AL, "Hypoxia--a key regulatory factor in tumour growth", Nat Rev Cancer, 2(1), pp.38~47 (2002)
- Azuma M, "Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients", Pharmacogenomics, 8(12), pp.1705~1713 (2007)
- Tas F, "Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer", Am J Clin Oncol, 24(4), pp.376~378 (2001)
- Gosavi SR, "Serum C-reactive protein in oral submucous fibrosis and oral squamous cell carcinoma : A cross-sectional study", J Oral Maxillofac Pathol, 24(1), pp.46~51 (2020)